- Home
- Publications
- Publication Search
- Publication Details
Title
Updated UK Recommendations for HER2 assessment in breast cancer
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL PATHOLOGY
Volume 68, Issue 2, Pages 93-99
Publisher
BMJ
Online
2014-12-09
DOI
10.1136/jclinpath-2014-202571
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The effect of delay in fixation on HER2 expression in invasive carcinoma of the breast assessed with immunohistochemistry and in situ hybridisation
- (2014) Andrew H S Lee et al. JOURNAL OF CLINICAL PATHOLOGY
- Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status
- (2013) Frédérique Penault-Llorca et al. BREAST
- Assessment of Her-2/neu status using immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology smears: Experience from a tertiary care centre in India
- (2013) Prashant Durgapal et al. DIAGNOSTIC CYTOPATHOLOGY
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity
- (2013) Wedad M Hanna et al. MODERN PATHOLOGY
- Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis
- (2012) Xiaosong Chen et al. BREAST CANCER RESEARCH AND TREATMENT
- Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast
- (2012) Andrew H S Lee et al. HISTOPATHOLOGY
- Does Breast Tumor Heterogeneity Necessitate Further Immunohistochemical Staining on Surgical Specimens?
- (2012) Lauren T. Greer et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH)
- (2012) Laurent Arnould et al. MODERN PATHOLOGY
- HeterogeneousHER2Gene Amplification
- (2011) Alastair I. Bartlett et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- HER2 genetic heterogeneity in breast carcinoma
- (2011) C. Ohlschlegel et al. JOURNAL OF CLINICAL PATHOLOGY
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- HER2and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial
- (2010) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
- (2010) Michael Untch et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
- (2010) M. Elizabeth H. Hammond et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2010) Luca Gianni et al. LANCET
- Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)
- (2009) M. Arnedos et al. ANNALS OF ONCOLOGY
- Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
- (2009) Guido Sauter et al. JOURNAL OF CLINICAL ONCOLOGY
- HER-2/neu analysis in breast cancer bone metastases
- (2009) J Zustin et al. JOURNAL OF CLINICAL PATHOLOGY
- Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
- (2008) Andrew D. Seidman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
- (2008) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 testing in the UK: further update to recommendations
- (2008) R A Walker et al. JOURNAL OF CLINICAL PATHOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started